6531-04-0

Basic information

• Product Name: 6-chloropyridazine-3-carbonyl chloride
• Synonyms: 6-chloropyridazine-3-carbonyl chloride;6-chloropyrazine-3-carboxylic acid chloride
• CAS NO: 6531-04-0
• Molecular Formula: C₅H₂Cl₂N₂O
• Molecular Weight: 176.99
• EINECS: -0
• Mol File: 6531-04-0.mol
• Article Data: 26

Chemical Properties

• Boiling Point: 231.9°C at 760 mmHg
• Flash Point: 94.1°C
• Appearance: /
• Density: 1.549g/cm³
• Vapor Pressure: 0.0608mmHg at 25°C
• Refractive Index: 1.571
• PKA: -1.52±0.10(Predicted)
• CAS DataBase Reference: 6-chloropyridazine-3-carbonyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 6-chloropyridazine-3-carbonyl chloride(6531-04-0)
• EPA Substance Registry System: 6-chloropyridazine-3-carbonyl chloride(6531-04-0)

Safety Data

• Hazardous Substances Data: 6531-04-0(Hazardous Substances Data)

Usage

General Description

6-chloropyridazine-3-carbonyl chloride is a chemical compound with the molecular formula C6H2ClN3O. It is a chlorinated derivative of pyridazine-3-carbonyl chloride, which is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. 6-chloropyridazine-3-carbonyl chloride is a reactive and versatile reagent widely employed in organic synthesis for the preparation of various heterocyclic compounds. It participates in reactions to form new carbon-carbon and carbon-nitrogen bonds, making it an important building block in the production of diverse chemical compounds. Additionally, it is also utilized in the development of new materials and in research applications for its unique reactivity and selectivity in chemical transformations.

InChI:InChI=1/C5H2Cl2N2O/c6-4-2-8-3(1-9-4)5(7)10/h1-2H

Upstream product

• 27372-38-9 6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid 
• 328-50-7 α-ketoglutaric acid 
• 37972-69-3 6-hydroxy-pyridazine-3-carboxylic acid 
• 75680-92-1 6-chloro-3-pyridazinecarboxylic acid ethyl ester 
• 1121-79-5 3-chloro-6-methylpyridazine 
• 37972-69-3 6-oxo-1,6-dihydropyridazine-3-carboxylic acid 
• 5096-73-1 6-chloro-pyridazine-3-carboxylic acid 

Downstream Products

• 65202-50-8 methyl 6-chloro-3-pyridazinecarboxylate 
• 1011487-94-7 (6-chloropyridazin-3-yl)methanol 
• 146233-34-3 3-chloro-6-(2-thienylcarbonyl)pyridazine 
• 960492-59-5 3-chloro-6-(5-methyl-1,3,4-oxadiazol-2-yl)pyridazine 
• 19194-96-8 methyl 6-methoxypyridazine-3-carboxylate 
• 1594103-29-3 C₁₄H₁₀ClN₃O 

Relevant articles and documents

Developing pyridazine-3-carboxamides to be CB2 agonists: The design, synthesis, structure-activity relationships and docking studies

Herein, we described the design and synthesis of a series of pyridazine-3-carboxamides to be CB2-selective agonists via a combination of scaffold hopping and bioisosterism strategies. The compounds were subjected to assessment of their potential activities through calcium mobilization assays. Among the tested derivatives, more than half of these compounds exhibited moderate to potent CB2 agonist activity. Six compounds showed EC50 values below 35 nM, and several derivatives also exhibited significantly enhanced potency and high selectivity at the CB2 receptor over the CB1 receptor. Specifically, compound 26 showed the highest CB2 agonist activity (EC50 = 3.665 ± 0.553 nM) and remarkable selectivity (Selectivity Index > 2729) against CB1. In addition, logPs of some representative compounds were measured to display significantly decreased values in comparison with GW842166X. Furthermore, docking simulations were conducted to explain the interaction mode of this series.

Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}- N-methylpyridine-2-carboxamide (AZD5305): A PARP1-DNA Trapper with High Selectivity for PARP1 over PARP2 and Other PARPs

Poly-ADP-ribose-polymerase (PARP) inhibitors have achieved regulatory approval in oncology for homologous recombination repair deficient tumors including BRCA mutation. However, some have failed in combination with first-line chemotherapies, usually due to overlapping hematological toxicities. Currently approved PARP inhibitors lack selectivity for PARP1 over PARP2 and some other 16 PARP family members, and we hypothesized that this could contribute to toxicity. Recent literature has demonstrated that PARP1 inhibition and PARP1-DNA trapping are key for driving efficacy in a BRCA mutant background. Herein, we describe the structure- and property-based design of 25 (AZD5305), a potent and selective PARP1 inhibitor and PARP1-DNA trapper with excellent in vivo efficacy in a BRCA mutant HBCx-17 PDX model. Compound 25 is highly selective for PARP1 over other PARP family members, with good secondary pharmacology and physicochemical properties and excellent pharmacokinetics in preclinical species, with reduced effects on human bone marrow progenitor cells in vitro.

BENZAMIDE DERIVATIVE

The present invention relates to a benzamide derivative of general formula I, a drug composition containing same and a use thereof as a drug, wherein the definitions of R1, Z and Q are as described in the description.